Early data from CAR macrophage trial show cell therapy is safe, feasible for solid tumors

early data from car macrophage trial show cell therapy is safe feasible for solid tumors

Sumary of Early data from CAR macrophage trial show cell therapy is safe, feasible for solid tumors:

  • November 17, 2021 3 min read Source/Disclosures Published by: Source: Reiss KA, et al.
  • Abstract 951. Presented at: Society for Immunotherapy of Cancer Annual Meeting;
  • Reiss reports advisory board roles with or research funding from Bristol Myers Squibb, Carisma Therapeutics, Clovis Oncology, Eli Lilly, GlaxoSmithKline and Tesaro.
  • Back to Healio Three patients have been safely treated with CT-0508, a novel cell-based therapy, according to initial results of a phase 1 trial presented at Society for the Immunotherapy of Cancer Annual Meeting.
  • CT-0508 (Carisma Therapeutics) is an autologous, gene-edited chimeric antigen receptor macrophage therapy that targets the HER2 protein in tumor cells.
  • The characteristics of macrophages and how they engage with tumors differs from that of T cells, which makes CAR macrophage therapy “a different modality” than CAR T cells, Kim A.
  • Reiss, MD, assistant professor of medicine in the division of hematology/oncology at Perelman School of Medicine at University of Pennsylvania, told Healio.
  • “CAR [macrophage] cells are highly present in the tumor microenvironment, and this particular product takes advantage of unique macrophage capabilities,” Reiss said.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.